Key result
Transdermal-to-sublingual buprenorphine protocol successfully transitions off methadone to reduce QT interval.
Why the study?
Methadone is associated with QT interval prolongation, and transitioning to buprenorphine/naloxone to reduce QT prolongation requires managing withdrawal that may affect treatment retention.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
Transitioning from high-dose methadone to buprenorphine/naloxone using a transdermal patch protocol can help manage methadone-induced QT prolongation.
Methadone and some psychiatric medications are associated with QT interval prolongation. Buprenorphine/naloxone, a newer medication for opioid use disorder, has a better safety profile than methadone including less QT interval prolongation. Transitioning to buprenorphine/naloxone, however, requires patients undergo an uncomfortable period of withdrawal which may discourage treatment retention in patients with severe opioid use disorder. We describe a case of high-dose methadone transition to buprenorphine/naloxone in order to decrease QT interval length and allow optimization of psychiatric medical therapy. A protocol for transitioning high-dose methadone to buprenorphine/naloxone using slow-release transdermal buprenorphine patch and careful initiation of sublingual buprenorphine/naloxone utilizing the Clinical Opiate Withdrawal Scale for monitoring is described. La méthadone et certains médicaments psychiatriques sont associés au prolongement de l'intervalle QT. La buprénorphine / naloxone, un médicament plus récent pour le trouble de l'utilisation des opioïdes, a un meilleur profil de sécurité que la méthadone, y compris moins de prolongement de l'intervalle QT. La transition vers la buprénorphine / naloxone, cependant, nécessite que les patients subissent une période de retrait inconfortable qui peut décourager la rétention du traitement chez les patients souffrant d'un trouble sévère de l'utilisation des opioïdes. Nous décrivons un cas de transition à la dose élevée de méthadone à la buprénorphine / naloxone afin de diminuer la durée de l'intervalle QT et d'optimiser le traitement médical psychiatrique. Un protocole pour la transition de la dose élevée de méthadone à la buprénorphine / naloxone à l'aide d'un patch de buprénorphine transdermique à libération lente et une amorce soigneuse au début de la buprénorphine / naloxone sublinguale en utilisant l’échelle clinique d’élimination des opiacés pour la surveillance est décrit.
No takes yet. Share an insight, caveat, or question.
Cortina et al. (2017) conducted a case report in Opioid use disorder with prolonged QT interval (n=1). Transition to buprenorphine/naloxone vs. High-dose methadone (baseline) was evaluated on Decrease QT interval length and allow optimization of psychiatric medical therapy. A protocol using a slow-release transdermal buprenorphine patch and careful initiation of sublingual buprenorphine/naloxone successfully transitioned a patient from high-dose methadone.
Synapse has enriched 10 related papers. Consider them for comparative context: